Dr. Verstovsek Discusses Immunotherapy in Myelofibrosis
Srdan Verstovsek, MD, PhD, the University of Texas MD Anderson Cancer Center, discusses immunotherapy in myelofibrosis.
Srdan Verstovsek, MD, PhD, professor, Department of Leukemia, Division of Cancer Medicine, the University of Texas MD Anderson Cancer Center, discusses immunotherapy in myelofibrosis.
Little is known about regulation in immune control in myelofibrosis, as well as how or whether this therapy will have any clinical applicability, Verstovsek says.
There is currently a study underway investigating nivolumab; Verstovsek and his colleagues are exploring the activity, as well as the biology of the disease, he says. Samples are looked at before therapy, and during therapy, to determine the underlying problem and how it is affected by therapy.
In all, Verstovsek believes there may be a clinical benefit with immunotherapies for the treatment of myelofibrosis.
Genetics and Ring Sideroblasts Impact ESA-Refractory Anemia in MDS
September 5th 2024During a Case-Based Roundtable® event, Azra Raza, MD, discussed a patient case of myelodysplastic syndrome first treated with erythropoiesis-stimulating agent in the second article of a 2-part series.
Read More
